• Home
  • R&D


OliX Pipeline

  • Pipeline
  • OLX101A
  • OLX201A
  • OLX301A
  • OLX301D

Idiopathic Pulmonary Fibrosis (IPF)

Scarring of lung tissue is a chronic, irreversible and fatal disease

Symptoms: chronic dry, hacking cough; fatigue and weakness; discomfort in the chest; loss of appetite; unexplained weight loss

Currently, there is no cost-effective therapeutics for the IPF

Market Potential

The number of IPF patients in the EU is estimated to be about 80,000~110,000. Approximately 30,000~35,000 new patients are emerging every year (Source : European IPF Charter)

Annual Potential IPF market: $900M in 2015 By 2025, expected to grow to $3.2B (Source : GlobalData Healthcare 2016)

Government Funding

A*STAR(Singapore)-KHIDI(Korea) Joint Grant Call: $1.8M / 3 years (2014.10~2017.09)
* KHIDI: Korea Health Industry Development Institute (www.khidi.or.kr)

Development Status

Outstanding efficacy identified from animal models